NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”)(NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that it has received a letter from the Food and Drug Administration providing the Company approval to commence a Phase II clinical trial in the U.S. for its Fibrin Patch product candidate in mild to moderate bleeding. The Company anticipates that the trial will commence in the second quarter of 2008 (2Q08).
